Senseonics and Sequel Med Tech Launch Integrated Type 1 Diabetes System

Senseonics and Sequel Med Tech have officially launched a new integrated system for people with Type 1 diabetes, combining the Eversense 365 continuous glucose monitor (CGM) with Sequel’s twiist automated insulin delivery (AID) pump.

Eversense 365 received clearance from the U.S. Food and Drug Administration in 2024 and is the first implantable CGM approved for use up to one year. Unlike wearable CGM patches from competitors such as Abbott and Dexcom, which typically last up to 15 days, Eversense is implanted under the skin and provides long-term glucose monitoring.

The companies initially targeted a 2025 launch but faced delays due to pump manufacturing scale-up. Commercial use began in early 2025, and Senseonics expects the system to contribute to revenue growth in 2026, although early sales may be limited by pump supply constraints.

27-02-2026